Ekaterina V. Kurbatova

National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial”.

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.105938

N/A

2.0DataRank · unranked

57 citations

Payam Nahid, Ekaterina V. Kurbatova, Stefan Goldberg, Lorna Bozeman, William J. Burman +27 more

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Clinical Infectious Diseases(2022)10.1093/cid/ciac707

N/A

0.726DataRank · unranked

13 citations

Patrick Phillips, Ekaterina V. Kurbatova, Andrew Vernon, Payam Nahid, Rodney Dawson +17 more

Optimizing drug inventory management with a web-based information system: The TBTC Study 31/ACTG A5349 experience

Contemporary Clinical Trials(2021)10.1016/j.cct.2021.106377

N/A

0.557DataRank · unranked

9 citations

Kara K. Lee, Claire Sadowski, Ekaterina V. Kurbatova, Stefan Goldberg, Pheona Nsubuga +13 more

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis

Contemporary Clinical Trials(2021)10.1016/j.cct.2021.106355

N/A

0.400DataRank · unranked

5 citations

Yan Yuan, Melissa Engle, Ekaterina V. Kurbatova, Cynthia Allen-Blige, Kumar Kunnal Batra +17 more

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Clinical Infectious Diseases(2021)10.1093/cid/ciab1037

N/A

0.365DataRank · unranked

5 citations

Michelle Pham, Erin Sizemore, Neil Martinson, Wadzanai Samaneka, Lerato Mohapi +20 more

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis

Clinical Infectious Diseases(2024)10.1093/cid/ciae119

N/A

0.306DataRank · unranked

6 citations

Ava Y Xu, Gustavo E. Velásquez, Nan Zhang, Vincent Chang, Ekaterina V. Kurbatova +16 more

Facilitators and barriers to adolescent participation in a TB clinical trial

The International Journal of Tuberculosis and Lung Disease(2024)10.5588/ijtld.23.0519

N/A

0.104DataRank · unranked

1 citations

Kimberly N. Chapman Hedges, M. M. Salerno, Kelsey Tatum, Beth Bouwkamp, Mike Frick +15 more

Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa042

N/A

0DataRank · unranked

20 citations

Ekaterina V. Kurbatova, Heather Alexander, Tracy Dalton, Michael P. Chen, James E. Posey +3 more

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.108075

N/A

0DataRank · unranked

0 citations

Kelly E. Dooley, Wendy Carr, Jason E. Stout, Eric Nuermberger, Patrick Phillips +22 more